• Citer

Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: An update of the pivotal clinical trial data

par Roex, Gils;Feys, Tom;Beguin, Yves;Kerre, Tessa;Poiré, Xavier;Lewalle, Philippe ;Vandenberghe, Peter;Bron, Dominique ;Anguille, Sébastien
Référence Pharmaceutics, 12, 2, 194
Publication Publié, 2020-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19-and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.